BioPharmSignal logoBioPharmSignal

Biotech News

Fulgent Presents Updated FID-007 Data at ASCO 2026

Fulgent Genetics, Inc. (FLGT)Fulgent Genetics, Inc.2026-06-25 13:46 ESTCompany update

EL MONTE, Calif. --(BUSINESS WIRE)--Jun. 1, 2026-- Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent” or the “Company”), a technology-based company with established laboratory services and therapeutic development businesses, today announced it presented updated data in the Head and Neck Cancer Track

Open original release

Related news

FLGTFulgent Genetics, Inc.2026-06-25 13:46 EST

Fulgent Announces Rapid Oral Full Abstract Publication for FID-007 Within the Head and Neck Cancer Track Session at the ASCO 2026 Annual Meeting

FLGTFulgent Genetics, Inc.2026-06-25 13:46 EST

Fulgent Shares Preliminary Data from Poster Presentation at ESMO 2025 Conference

FLGTFulgent Genetics, Inc.2026-06-25 13:46 EST

Fulgent Reports Third Quarter 2025 Financial Results

FLGTFulgent Genetics, Inc.2026-06-25 13:46 EST

Fulgent to Participate in Upcoming Conferences

FLGTFulgent Genetics, Inc.2026-06-25 13:46 EST

Fulgent Genetics Agrees to Acquire Bako Diagnostics and StrataDx

FLGTFulgent Genetics, Inc.2026-06-25 13:46 EST

Fulgent to Announce Fourth Quarter and Full Year 2025 Financial Results on Friday, February 27, 2026

FLGTFulgent Genetics, Inc.2026-06-25 13:46 EST

Fulgent Reports Fourth Quarter and Full Year 2025 Financial Results

FLGTFulgent Genetics, Inc.2026-06-25 13:46 EST

Fulgent Genetics Completes Acquisition of Bako Diagnostics and StrataDx

FLGTFulgent Genetics, Inc.2026-06-25 13:46 EST

Fulgent to Announce First Quarter 2026 Financial Results on Friday, May 1, 2026

FLGTFulgent Genetics, Inc.2026-06-25 13:46 EST

Fulgent Reports First Quarter 2026 Financial Results

View all latest news

Fulgent Genetics, Inc.

Fulgent Genetics is a biopharmaceutical company focused on advancing a pipeline of therapeutic programs. Investors usually track how clinical data, regulatory milestones, and launch execution change the story over time.

Recent company news

FLGTFulgent Genetics, Inc.2026-06-26 10:02 EST

Fulgent Presents Updated FID-007 Data at ASCO 2026

FLGTFulgent Genetics, Inc.2026-06-26 10:02 EST

Fulgent Announces Rapid Oral Full Abstract Publication for FID-007 Within the Head and Neck Cancer Track Session at the ASCO 2026 Annual Meeting

FLGTFulgent Genetics, Inc.2026-06-26 10:02 EST

Fulgent Shares Preliminary Data from Poster Presentation at ESMO 2025 Conference

FLGTFulgent Genetics, Inc.2026-06-26 10:02 EST

Fulgent Reports Third Quarter 2025 Financial Results

FLGTFulgent Genetics, Inc.2026-06-26 10:02 EST

Fulgent to Participate in Upcoming Conferences

Stock data

Close
—
Market cap
—
Exchange
NASDAQ
Sector
Biotechnology
Location
United States